Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Gliosarcoma × Drug Therapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Breast Neoplasms 12 Neoplasms 9 Carcinoma, Squamous Cell 8 Head and Neck Neoplasms 7 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Lung Neoplasms 6 Glioblastoma 6 Colorectal Neoplasms 6 Recurrence 5 Melanoma 5 Leukemia, Myeloid, Acute 5 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Leukemia 4 Small Cell Lung Carcinoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Follicular 3 Fallopian Tube Neoplasms 3 Colonic Neoplasms 3 Brain Neoplasms 3 Treatment 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Rectal Neoplasms 2 Mouth Neoplasms 2 Mesothelioma, Malignant 2 Lymphoma, T-Cell, Peripheral 2

Interventions

Temozolomide 48 Bevacizumab 31 Radiotherapy 24 Radiation 11 Erlotinib Hydrochloride 11 Radiotherapy, Intensity-Modulated 7 Radiotherapy, Conformal 7 Irinotecan 6 Vorinostat 5 Immunoglobulin G 4 Disulfides 4 Carmustine 4 plerixafor 3 carmustine, poliferprosan 20 drug combination 3 Sorafenib 3 Sirolimus 3 Radiosurgery 3 Magnetic Resonance Spectroscopy 3 Everolimus 3 Dasatinib 3 Bortezomib 3 veliparib 2 vandetanib 2 temsirolimus 2 tandutinib 2 sargramostim 2 pazopanib 2 ferric pyrophosphate 2 cediranib 2 Topotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01822275 2022-12-29

GCC 1224

University of Maryland, Baltimore

Phase 2 Terminated

24 enrolled 9 charts

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡